Pramlintide
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
AstraZeneca · Phase 2 · Terminated · Enrollment 213
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Group A | Obesity or overweight | n/r | 16 | n/r | n/r |
| Group B | Obesity or overweight | n/r | 16 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Pramlintide + Metreleptin | Obesity or overweight | n/r | n/r | n/r | n/r |